Prognostic impact of blood Epstein-Barr virus-DNA in patients with peripheral T-cell lymphoma, not otherwise specified.

Authors

Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan-Sik Park, Eun Jin Chae, Kyung Won Kim, Jin-Sook Ryu, Sang-Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon

Published in

British journal of haematology. Aug 07, 2026. Epub Aug 07, 2026.

Abstract

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a heterogeneous nodal T- and natural killer (NK)-cell lymphoma with limited prognostic biomarkers. A subset of PTCL-NOS characterized by Epstein-Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV-positive nodal T- and NK-cell lymphoma (EBV+ nPTCL), a distinct entity in the fifth edition of the World Health Organization classification of haematolymphoid neoplasms (WHO-HAEM5). However, the clinical significance of circulating EBV deoxyribonucleic acid (DNA) in PTCL-NOS remains unclear. Patients initially diagnosed with PTCL-NOS who received first-line systemic chemotherapy at a single-centre between 2007 and 2025 were retrospectively analysed. Cases were reclassified according to WHO-HAEM5 using EBV-encoded small ribonucleic acid (EBER) in situ hybridization and pathological review. Among 101 patients, 4 were reclassified as EBV+ nPTCL using a ≥50% tumour cell EBER positivity cut-off and excluded, yielding a cohort of 97 patients with WHO-HAEM5-defined PTCL-NOS. Baseline blood EBV-DNA positivity was observed in 42.3%. EBV-DNA-positive patients demonstrated significantly shorter progression-free and overall survival (OS) compared with EBV-DNA-negative patients. In multivariate analyses, EBV-DNA positivity independently predicted poorer survival outcomes. Exploratory analyses indicated that EBV-DNA clearance during chemotherapy was associated with improved OS. These findings suggest that blood EBV-DNA may serve as a prognostic biomarker in patients with PTCL-NOS.

PMID:
42567844
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.